The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A proprietary multianalyte test for predicting extreme resistance to neoadjuvant 5-FU based chemoradiation (CTRT) in esophageal adenocarcinoma (EC).
Weiwei Shan
Stock Ownership - Castle Biosciences
Research Funding - Castle Biosciences
Natalie Lassen
Research Funding - Castle Biosciences
Clare Johnson
Stock Ownership - Castle Biosciences
Research Funding - Castle Biosciences
Yaeli Biermann-Harrar
No relevant relationships to disclose
Kristen M. Oelschlager
Stock Ownership - Castle Biosciences
Research Funding - Castle Biosciences
Robert W. Cook
Stock Ownership - Castle Biosciences
Research Funding - Castle Biosciences
Daniel Rosen
No relevant relationships to disclose
Sunil S. Badve
No relevant relationships to disclose
Kenneth Kessler
No relevant relationships to disclose
Romil Saxena
No relevant relationships to disclose